- Home
- ADVM vs SVII Comparison
ADVM vs SVII Comparison
Compare ADVM & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- SVII
- Stock Information
- Founded
- ADVM 2006
- SVII 2021
- Country
- ADVM United States
- SVII United States
- Employees
- ADVM N/A
- SVII N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- SVII Blank Checks
- Sector
- ADVM Health Care
- SVII Finance
- Exchange
- ADVM Nasdaq
- SVII Nasdaq
- Market Cap
- ADVM 119.6M
- SVII 111.1M
- IPO Year
- ADVM 2014
- SVII 2022
- Fundamental
- Price
- ADVM $4.74
- SVII $11.22
- Analyst Decision
- ADVM Strong Buy
- SVII
- Analyst Count
- ADVM 6
- SVII 0
- Target Price
- ADVM $27.83
- SVII N/A
- AVG Volume (30 Days)
- ADVM 226.5K
- SVII 74.3K
- Earning Date
- ADVM 11-04-2024
- SVII 01-01-0001
- Dividend Yield
- ADVM N/A
- SVII N/A
- EPS Growth
- ADVM N/A
- SVII 13.16
- EPS
- ADVM N/A
- SVII 0.36
- Revenue
- ADVM $1,000,000.00
- SVII N/A
- Revenue This Year
- ADVM N/A
- SVII N/A
- Revenue Next Year
- ADVM $1,342.84
- SVII N/A
- P/E Ratio
- ADVM N/A
- SVII $31.17
- Revenue Growth
- ADVM N/A
- SVII N/A
- 52 Week Low
- ADVM $4.59
- SVII $10.81
- 52 Week High
- ADVM $29.70
- SVII $11.70
- Technical
- Relative Strength Index (RSI)
- ADVM 26.02
- SVII 42.27
- Support Level
- ADVM $4.59
- SVII $11.20
- Resistance Level
- ADVM $4.89
- SVII $11.24
- Average True Range (ATR)
- ADVM 0.31
- SVII 0.01
- MACD
- ADVM -0.06
- SVII 0.01
- Stochastic Oscillator
- ADVM 9.80
- SVII 49.40
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.